Physician profile
Nathan S Kusterer
NPI 1790078764
$8,289.24
in general payments reported to CMS, 2019-2025
40 companies · $1,772 in 2025
The $1,772 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,198 · 2020: $693 · 2021: $856 · 2022: $877 · 2023: $885 · 2024: $1,008 · 2025: $1,772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,665.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,665.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,461.09 | 2019-2025 | Cardiomems, Amplatzer Talisman, Mitraclip |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,103.82 | 2019-2025 | Lifevest |
| Boston Scientific Corporation | $767.08 | 2019-2025 | General - Therapies, Emblem Mri S-Icd, Lux-Dx Insertable Cardiac Monitor |
| Aop Health US, LLC | $767.00 | 2025 | Rapiblyk |
| Pfizer INC. | $689.13 | 2019-2025 | |
| Amgen INC. | $516.13 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $487.95 | 2019-2024 | Brilinta, Farxiga, Andexxa |
| Janssen Pharmaceuticals, INC | $338.77 | 2020-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $179.53 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.50 | 2019-2025 | Jardiance |
| Esperion Therapeutics, INC. | $151.26 | 2020-2022 | |
| Impulse Dynamics (USA) INC. | $142.47 | 2022-2025 | Optimizer |
| Actelion Pharmaceuticals US, INC. | $139.15 | 2020-2021 | |
| Philips North America LLC | $131.42 | 2020-2025 | (5091) Amb Mon & Diag Und, Ambulatory Monitoring & Diagnostics Undivided |
| Sanofi-Aventis U.S. LLC | $129.82 | 2019-2022 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $127.49 | 2019-2025 | Onpattro |
| Bayer Healthcare Pharmaceuticals INC. | $121.87 | 2022-2025 | |
| Novo Nordisk INC | $90.98 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $87.04 | 2022-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $85.73 | 2022-2025 | Verquvo |
| Regeneron Healthcare Solutions, INC. | $82.42 | 2019 | |
| Medtronic, INC. | $74.04 | 2022-2023 | Linq II, Corevalve Evolut R |
| Atricure, INC. | $60.76 | 2022-2024 | |
| Amarin Pharma, INC. | $43.87 | 2019-2020 | |
| Bridgebio Pharma, INC. | $43.55 | 2025 | Attruby |
| Edwards Lifesciences Corporation | $34.22 | 2025 | Sapien 3 Ultra Resilia |
| Portola Pharmaceuticals, LLC | $28.51 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $24.72 | 2024 | Arcalyst |
| Kestra Medical Technology Services, INC. | $24.35 | 2025 | Assure Wcd |
| Ge Healthcare | $23.84 | 2023 | |
| Cvrx, INC. | $23.70 | 2022 | |
| Angiodynamics, INC. | $18.24 | 2024 | Alphavac |
| Lilly USA, LLC | $18.00 | 2025 | Zepbound |
| Akcea Therapeutics, INC. | $15.32 | 2021 | |
| Cardiva Medical, INC. | $13.93 | 2023 | Cardiva Vascade 6/7f Vcs |
| Lexicon Pharmaceuticals, INC. | $13.91 | 2023 | Inpefa |
| Heartflow, INC. | $13.88 | 2025 | |
| Medtronic Vascular, INC. | $13.38 | 2019 | |
| Chiesi USA, INC. | $13.22 | 2019 | |
| Lundbeck LLC | $12.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Kusterer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.